Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 12/2014

Open Access 01-12-2014 | Inflammatory Muscle Disease (RG Cooper, Section Editor)

Ongoing Developments in Sporadic Inclusion Body Myositis

Authors: Pedro M. Machado, Mhoriam Ahmed, Stefen Brady, Qiang Gang, Estelle Healy, Jasper M. Morrow, Amanda C. Wallace, Liz Dewar, Gita Ramdharry, Matthew Parton, Janice L. Holton, Henry Houlden, Linda Greensmith, Michael G. Hanna

Published in: Current Rheumatology Reports | Issue 12/2014

Login to get access

Abstract

Sporadic inclusion body myositis (IBM) is an acquired muscle disorder associated with ageing, for which there is no effective treatment. Ongoing developments include: genetic studies that may provide insights regarding the pathogenesis of IBM, improved histopathological markers, the description of a new IBM autoantibody, scrutiny of the diagnostic utility of clinical features and biomarkers, the refinement of diagnostic criteria, the emerging use of MRI as a diagnostic and monitoring tool, and new pathogenic insights that have led to novel therapeutic approaches being trialled for IBM, including treatments with the objective of restoring protein homeostasis and myostatin blockers. The effect of exercise in IBM continues to be investigated. However, despite these ongoing developments, the aetiopathogenesis of IBM remains uncertain. A translational and multidisciplinary collaborative approach is critical to improve the diagnosis, treatment, and care of patients with IBM.
Literature
1.
Lindberg C, Persson LI, Bjorkander J, Oldfors A. Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases. Acta Neurol Scand. 1994;89(2):123–31.PubMed
2.
Badrising UA, Maat-Schieman M, van Duinen SG, et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology. 2000;55(9):1385–7.PubMed
3.
Kaipiainen-Seppanen O, Aho K. Incidence of rare systemic rheumatic and connective tissue diseases in Finland. J Intern Med. 1996;240(2):81–4.PubMed
4.
Phillips BA, Zilko PJ, Mastaglia FL. Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve. 2000;23(6):970–2.PubMed
5.
Felice KJ, North WA. Inclusion body myositis in Connecticut: observations in 35 patients during an 8-year period. Medicine. 2001;80(5):320–7.PubMed
6.
Needham M, Corbett A, Day T, Christiansen F, Fabian V, Mastaglia FL. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci Off J Neurosurg Soc Australas. 2008;15(12):1350–3.
7.
Wilson FC, Ytterberg SR, St Sauver JL, Reed AM. Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. J Rheumatol. 2008;35(3):445–7.PubMed
8.
Oflazer PS, Deymeer F, Parman Y. Sporadic-inclusion body myositis (s-IBM) is not so prevalent in Istanbul/Turkey: a muscle biopsy based survey. Acta myologica: myopathies and cardiomyopathies: official journal of the Mediterranean Society of Myology/edited by the Gaetano Conte Academy for the study of striated muscle diseases 2011;30(1):34–6.
9.
Suzuki N, Aoki M, Mori-Yoshimura M, Hayashi YK, Nonaka I, Nishino I. Increase in number of sporadic inclusion body myositis (sIBM) in Japan. J Neurol. 2012;259(3):554–6.PubMed
10.
Tan JA, Roberts-Thomson PJ, Blumbergs P, Hakendorf P, Cox SR, Limaye V. Incidence and prevalence of idiopathic inflammatory myopathies in South Australia: a 30-year epidemiologic study of histology-proven cases. Int J Rheum Dis. 2013;16(3):331–8.PubMed
11.
Ringel SP, Kenny CE, Neville HE, Giorno R, Carry MR. Spectrum of inclusion body myositis. Arch Neurol. 1987;44(11):1154–7.PubMed
12.
Dimachkie MM, Barohn RJ. Inclusion body myositis. Curr Neurol Neurosci Rep. 2013;13(1):321.PubMed
13.
14.•
Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain J Neurol. 2011;134(Pt 11):3176–84. Large retrospective study describing the clinical and demographic features of IBM and progression over time.
15.
Breithaupt M, Schmidt J. Update on treatment of inclusion body myositis. Curr Rheumatol Rep. 2013;15(5):329.PubMed
16.
Lloyd TE. Novel therapeutic approaches for inclusion body myositis. Curr Opin Rheumatol. 2010;22(6):658–64.PubMed
17.••
Gang Q, Bettencourt C, Machado P, Hanna MG, Houlden H. Sporadic inclusion body myositis: the genetic contributions to the pathogenesis. Orphanet J Rare Dis. 2014;9:88. Comprehensive review of genetic susceptibility risk factors for IBM. PubMedCentralPubMed
18.
Koffman BM, Sivakumar K, Simonis T, Stroncek D, Dalakas MC. HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies. J Neuroimmunol. 1998;84(2):139–42.PubMed
19.
Garlepp MJ, Laing B, Zilko PJ, Ollier W, Mastaglia FL. HLA associations with inclusion body myositis. Clin Exp Immunol. 1994;98(1):40–5.PubMedCentralPubMed
20.
Lampe JB, Gossrau G, Kempe A, et al. Analysis of HLA class I and II alleles in sporadic inclusion-body myositis. J Neurol. 2003;250(11):1313–7.PubMed
21.
Badrising UA, Schreuder GM, Giphart MJ, et al. Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis. Neurology. 2004;63(12):2396–8.PubMed
22.
Price P, Santoso L, Mastaglia F, et al. Two major histocompatibility complex haplotypes influence susceptibility to sporadic inclusion body myositis: critical evaluation of an association with HLA-DR3. Tissue Antigens. 2004;64(5):575–80.PubMed
23.
O’Hanlon TP, Carrick DM, Arnett FC, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in caucasians. Medicine. 2005;84(6):338–49.PubMed
24.
Needham M, James I, Corbett A, et al. Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry. 2008;79(9):1056–60.PubMed
25.
Mastaglia FL, Needham M, Scott A, et al. Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype. Neuromuscul Dis. 2009;19(11):763–5.
26.
Rojana-udomsart A, James I, Castley A, et al. High-resolution HLA-DRB1 genotyping in an Australian inclusion body myositis (s-IBM) cohort: an analysis of disease-associated alleles and diplotypes. J Neuroimmunol. 2012;250(1–2):77–82.PubMed
27.
Scott AP, Allcock RJ, Mastaglia F, Nishino I, Nonaka I, Laing N. Sporadic inclusion body myositis in Japanese is associated with the MHC ancestral haplotype 52.1. Neuromuscul Dis. 2006;16(5):311–5.
28.
Scott AP, Laing NG, Mastaglia F, et al. Recombination mapping of the susceptibility region for sporadic inclusion body myositis within the major histocompatibility complex. J Neuroimmunol. 2011;235(1–2):77–83.PubMed
29.
Scott AP, Laing NG, Mastaglia F, Dalakas M, Needham M, Allcock RJ. Investigation of NOTCH4 coding region polymorphisms in sporadic inclusion body myositis. J Neuroimmunol. 2012;250(1–2):66–70.PubMed
30.••
Pluk H, van Hoeve BJ, van Dooren SH, et al. Autoantibodies to cytosolic 5′-nucleotidase 1A in inclusion body myositis. Ann Neurol. 2013;73(3):397–407. Description and diagnostic performance of autoantibodies against cytosolic 5′-nucleotidase 1A in IBM. PubMed
31.••
Larman HB, Salajegheh M, Nazareno R, et al. Cytosolic 5′-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol. 2013;73(3):408–18. Description and diagnostic performance of autoantibodies against cytosolic 5′-nucleotidase 1A in IBM. PubMed
32.
Askanas V, Alvarez RB, Engel WK. beta-Amyloid precursor epitopes in muscle fibers of inclusion body myositis. Ann Neurol. 1993;34(4):551–60.PubMed
33.
Sivakumar K, Cervenakova L, Dalakas MC, et al. Exons 16 and 17 of the amyloid precursor protein gene in familial inclusion body myopathy. Ann Neurol. 1995;38(2):267–9.PubMed
34.
Needham M, Hooper A, James I, et al. Apolipoprotein epsilon alleles in sporadic inclusion body myositis: a reappraisal. Neuromuscul Dis. 2008;18(2):150–2.
35.
Hernandez-Charro B, Moreno S, Valiente A, Manubens JM, Villar MD, Ramos-Arroyo MA. ACT/AA polymorphism could duplicate the APOE*epsilon4-associated Alzheimer’s disease risk. Med Clin. 2004;123(7):251–4.
36.
Askanas V, Bilak M, Engel WK, Alvarez RB, Tome F, Leclerc A. Prion protein is abnormally accumulated in inclusion-body myositis. Neuroreport. 1993;5(1):25–8.PubMed
37.
Lampe J, Kitzler H, Walter MC, Lochmuller H, Reichmann H. Methionine homozygosity at prion gene codon 129 may predispose to sporadic inclusion-body myositis. Lancet. 1999;353(9151):465–6.PubMed
38.
Orth M, Tabrizi SJ, Schapira AH. Sporadic inclusion body myositis not linked to prion protein codon 129 methionine homozygosity. Neurology. 2000;55(8):1235.PubMed
39.
Olive M, Janue A, Moreno D, Gamez J, Torrejon-Escribano B, Ferrer I. TAR DNA-Binding protein 43 accumulation in protein aggregate myopathies. J Neuropathol Exp Neurol. 2009;68(3):262–73.PubMed
40.
Salajegheh M, Pinkus JL, Taylor JP, et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve. 2009;40(1):19–31.PubMedCentralPubMed
41.
Hernandez Lain A, Millecamps S, Dubourg O, et al. Abnormal TDP-43 and FUS proteins in muscles of sporadic IBM: similarities in a TARDBP-linked ALS patient. J Neurol Neurosurg Psychiatry. 2011;82(12):1414–6.PubMed
42.
Oldfors A, Larsson NG, Lindberg C, Holme E. Mitochondrial DNA deletions in inclusion body myositis. Brain J Neurol. 1993;116(Pt 2):325–36.
43.
Santorelli FM, Sciacco M, Tanji K, et al. Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: a study of 56 patients. Ann Neurol. 1996;39(6):789–95.PubMed
44.
Moslemi AR, Lindberg C, Oldfors A. Analysis of multiple mitochondrial DNA deletions in inclusion body myositis. Hum Mutat. 1997;10(5):381–6.PubMed
45.
Oldfors A, Moslemi AR, Jonasson L, Ohlsson M, Kollberg G, Lindberg C. Mitochondrial abnormalities in inclusion-body myositis. Neurology. 2006;66(2 Suppl 1):S49–55.PubMed
46.
Guerreiro RJ, Hardy J. TOMM40 association with Alzheimer disease: tales of APOE and linkage disequilibrium. Arch Neurol. 2012;69(10):1243–4.PubMed
47.
Mastaglia FL, Rojana-Udomsart A, James I, et al. Polymorphism in the TOMM40 gene modifies the risk of developing sporadic inclusion body myositis and the age of onset of symptoms. NMD: Neuromuscular disorders; 2013.
48.
Tateyama M, Saito N, Fujihara K, et al. Familial inclusion body myositis: a report on two Japanese sisters. Intern Med (Tokyo, Jpn). 2003;42(10):1035–8.
49.
Sivakumar K, Semino-Mora C, Dalakas MC. An inflammatory, familial, inclusion body myositis with autoimmune features and a phenotype identical to sporadic inclusion body myositis. Stud Three Fam Brain J Neurol. 1997;120(Pt 4):653–61.
50.
Ranque-Francois B, Maisonobe T, Dion E, et al. Familial inflammatory inclusion body myositis. Ann Rheum Dis. 2005;64(4):634–7.PubMedCentralPubMed
51.
Cai H, Yabe I, Sato K, et al. Clinical, pathological, and genetic mutation analysis of sporadic inclusion body myositis in Japanese people. J Neurol. 2012;259(9):1913–22.PubMed
52.
Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol. 1995;38(5):705–13.PubMed
53.
Amato AA, Gronseth GS, Jackson CE, et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol. 1996;40(4):581–6.PubMed
54.
Brady S, Squier W, Hilton-Jones D. Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features. J Neurol Neurosurg Psychiatry. 2013;84(11):1240–6.PubMed
55.
Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol. 1984;16(2):193–208.PubMed
56.••
Brady S, Squier W, Sewry C, Hanna M, Hilton-Jones D, Holton JL. A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis. BMJ Open. 2014;4(4):e004552. Study investigating the diagnostic utility of the histopathological features associated with IBM and proposing a diagnostic algorithm. PubMedCentralPubMed
57.
Greenberg SA. How citation distortions create unfounded authority: analysis of a citation network. BMJ. 2009;339:b2680.PubMedCentralPubMed
58.•
Hiniker A, Daniels BH, Lee HS, Margeta M. Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies. Acta Neuropathol Commun. 2013;1(1):29. Quantitative study of the diagnostic value of LC3, p62, and TDP-43 immunohistochemistry in IBM. PubMedCentralPubMed
59.
Salajegheh M, Lam T, Greenberg SA. Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PLoS One. 2011;6(5):e20266.PubMedCentralPubMed
60.
Greenberg SA. Cytoplasmic 5′-nucleotidase autoantibodies in inclusion body myositis: isotypes and diagnostic utility. Muscle Nerve 2014.
61.
62.
Cantwell C, Ryan M, O’Connell M, et al. A comparison of inflammatory myopathies at whole-body turbo STIR MRI. Clin Radiol. 2005;60(2):261–7.PubMed
63.•
Cox FM, Reijnierse M, van Rijswijk CS, Wintzen AR, Verschuuren JJ, Badrising UA. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology. 2011;50(6):1153–61. Cross-sectional study of upper and lower extremity muscle MRI in a group of 32 patients with IBM. PubMed
64.
Phillips BA, Cala LA, Thickbroom GW, Melsom A, Zilko PJ, Mastaglia FL. Patterns of muscle involvement in inclusion body myositis: clinical and magnetic resonance imaging study. Muscle Nerve. 2001;24(11):1526–34.PubMed
65.
Sekul EA, Chow C, Dalakas MC. Magnetic resonance imaging of the forearm as a diagnostic aid in patients with sporadic inclusion body myositis. Neurology. 1997;48(4):863–6.PubMed
66.
Reimers CD, Schedel H, Fleckenstein JL, et al. Magnetic resonance imaging of skeletal muscles in idiopathic inflammatory myopathies of adults. J Neurol. 1994;241(5):306–14.PubMed
67.
Glover GH, Schneider E. Three-point Dixon technique for true water/fat decomposition with B0 inhomogeneity correction. Magn Reson Medi Off J Soc Magn Reson Med Soc Magn Reson Med. 1991;18(2):371–83.
68.
Jurkat-Rott K, Weber MA, Fauler M, et al. K+-dependent paradoxical membrane depolarization and Na+overload, major and reversible contributors to weakness by ion channel leaks. Proc Natl Acad Sci U S A. 2009;106(10):4036–41.PubMedCentralPubMed
69.
Morrow JM, Sinclair CD, Fischmann A, et al. Reproducibility, and age, body-weight and gender dependency of candidate skeletal muscle MRI outcome measures in healthy volunteers. Eur Radiol. 2014.
70.
Morrow J, Sinclair CDJ, Fischmann A, et al. MRI quantification of lower limb muscle fatty atrophy: a potential outcome measure in chronic neuromuscular diseases. J Neurol Neurosurg Psychiatry. 2012;83:e1.
71.•
Rose MR, Group EIW. 188th ENMC International Workshop: inclusion body myositis, 2-4 December 2011, Naarden, The Netherlands. Neuromuscul Dis. 2013;23(12):1044–55. Report of an international workshop that resulted in the publication of revised research diagnostic criteria for IBM.
72.
Hilton-Jones D, Miller A, Parton M, Holton J, Sewry C, Hanna MG. Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008. Neuromuscul Dis. 2010;20(2):142–7.
73.
Benveniste O, Hilton-Jones D. International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009. Neuromuscul Dis. 2010;20(6):414–21.
74.••
Lloyd TE, Mammen AL, Amato AA, Weiss MD, Needham M, Greenberg SA. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology 2014. Analysis of the diagnostic performance of published IBM diagnostic categories and individual IBM features.
75.
Needham M, Mastaglia FL. Sporadic inclusion body myositis: a continuing puzzle. Neuromuscul Dis. 2008;18(1):6–16.
76.
77.
Dalakas MC. Sporadic inclusion body myositis–diagnosis, pathogenesis and therapeutic strategies. Nature clinical practice. Neurology. 2006;2(8):437–47.PubMed
78.
Askanas V, Engel WK. Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis. Curr Opin Rheumatol. 2007;19(6):550–9.PubMed
79.
Georgantas RW, Streicher K, Greenberg SA, et al. Inhibition of myogenic microRNAs 1, 133, and 206 by inflammatory cytokines links inflammation and muscle degeneration in adult inflammatory myopathies. Arthritis Rheumatol. 2014;66(4):1022–33.PubMed
80.
Rygiel KA, Miller J, Grady JP, Rocha MC, Taylor RW, Turnbull DM. Mitochondrial and inflammatory changes in sporadic Inclusion Body Myositis. Neuropathol Appl Neurobiol. 2014.
81.
Temiz P, Weihl CC, Pestronk A. Inflammatory myopathies with mitochondrial pathology and protein aggregates. J Neurol Sci. 2009;278(1–2):25–9.PubMed
82.
Pinkus JL, Amato AA, Taylor JP, Greenberg SA. Abnormal distribution of heterogeneous nuclear ribonucleoproteins in sporadic inclusion body myositis. Neuromuscul Dis. 2014;24(7):611–6.
83.
Cortese A, Plagnol V, Brady S, et al. Widespread RNA metabolism impairment in sporadic inclusion body myositis TDP43-proteinopathy. Neurobiol Aging. 2014;35(6):1491–8.PubMedCentralPubMed
84.
Greenberg SA, Pinkus JL, Amato AA. Nuclear membrane proteins are present within rimmed vacuoles in inclusion-body myositis. Muscle Nerve. 2006;34(4):406–16.PubMed
85.
Nakano S, Shinde A, Fujita K, Ito H, Kusaka H. Histone H1 is released from myonuclei and present in rimmed vacuoles with DNA in inclusion body myositis. Neuromuscul Dis. 2008;18(1):27–33.
86.
Nalbantoglu J, Karpati G, Carpenter S. Conspicuous accumulation of a single-stranded DNA binding protein in skeletal muscle fibers in inclusion body myositis. Am J Pathol. 1994;144(5):874–82.PubMedCentralPubMed
87.
Nogalska A, Terracciano C, D’Agostino C, King Engel W, Askanas V. p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis. Acta Neuropathol. 2009;118(3):407–13.PubMed
88.
D’Agostino C, Nogalska A, Engel WK, Askanas V. In sporadic inclusion body myositis muscle fibres TDP-43-positive inclusions are less frequent and robust than p62 inclusions, and are not associated with paired helical filaments. Neuropathol Appl Neurobiol. 2011;37(3):315–20.PubMed
89.
Ju JS, Weihl CC. p97/VCP at the intersection of the autophagy and the ubiquitin proteasome system. Autophagy. 2010;6(2):283–5.PubMedCentralPubMed
90.
Askanas V, Engel WK, Nogalska A. Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation. Brain Pathol (Zurich, Switzerland). 2009;19(3):493–506.
91.
Weihl CC, Pestronk A. Sporadic inclusion body myositis: possible pathogenesis inferred from biomarkers. Curr Opin Neurol. 2010;23(5):482–8.PubMedCentralPubMed
92.
Ferrer I, Martin B, Castano JG, Lucas JJ, Moreno D, Olive M. Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. J Neuropathol Exp Neurol. 2004;63(5):484–98.PubMed
93.
Fratta P, Engel WK, Van Leeuwen FW, Hol EM, Vattemi G, Askanas V. Mutant ubiquitin UBB+1 is accumulated in sporadic inclusion-body myositis muscle fibers. Neurology. 2004;63(6):1114–7.PubMed
94.
Cacciottolo M, Nogalska A, D’Agostino C, Engel WK, Askanas V. Chaperone-mediated autophagy components are upregulated in sporadic inclusion-body myositis muscle fibres. Neuropathol Appl Neurobiol. 2013;39(7):750–61.PubMed
95.
Girolamo F, Lia A, Amati A, et al. Overexpression of autophagic proteins in the skeletal muscle of sporadic inclusion body myositis. Neuropathol Appl Neurobiol. 2013;39(7):736–49.PubMed
96.
D’Agostino C, Nogalska A, Cacciottolo M, Engel WK, Askanas V. Abnormalities of NBR1, a novel autophagy-associated protein, in muscle fibers of sporadic inclusion-body myositis. Acta Neuropathol. 2011;122(5):627–36.PubMed
97.
Vattemi G, Engel WK, McFerrin J, Askanas V. Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle. Am J Pathol. 2004;164(1):1–7.PubMedCentralPubMed
98.
Weihl CC, Dalal S, Pestronk A, Hanson PI. Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation. Hum Mol Genet. 2006;15(2):189–99.PubMed
99.
Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol. 1998;143(7):1883–98.PubMedCentralPubMed
100.
Liu Y, Gampert L, Nething K, Steinacker JM. Response and function of skeletal muscle heat shock protein 70. Front Biosci J Virtual Libr. 2006;11:2802–27.
101.
Kollias HD, McDermott JC. Transforming growth factor-beta and myostatin signaling in skeletal muscle. J Appl Physiol. 2008;104(3):579–87.PubMed
102.
McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387(6628):83–90.PubMed
103.
Kambadur R, Sharma M, Smith TP, Bass JJ. Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Genome Res. 1997;7(9):910–6.PubMed
104.
McPherron AC, Lee SJ. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci U S A. 1997;94(23):12457–61.PubMedCentralPubMed
105.
Mosher DS, Quignon P, Bustamante CD, et al. A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet. 2007;3(5):e79.PubMedCentralPubMed
106.
Schuelke M, Wagner KR, Stolz LE, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med. 2004;350(26):2682–8.PubMed
107.
Carnac G, Ricaud S, Vernus B, Bonnieu A. Myostatin: biology and clinical relevance. Mini Rev Med Chem. 2006;6(7):765–70.PubMed
108.
Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008;63(5):561–71.PubMed
109.
110.
Bogdanovich S, McNally EM, Khurana TS. Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C. Muscle Nerve. 2008;37(3):308–16.PubMed
111.
Bartoli M, Poupiot J, Vulin A, et al. AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not alpha-sarcoglycan deficiency. Gene Ther. 2007;14(9):733–40.PubMed
112.
Cadena SM, Tomkinson KN, Monnell TE, et al. Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. J Appl Physiol. 2010;109(3):635–42.PubMedCentralPubMed
113.
Rodino-Klapac LR, Haidet AM, Kota J, Handy C, Kaspar BK, Mendell JR. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve. 2009;39(3):283–96.PubMedCentralPubMed
114.
Haidet AM, Rizo L, Handy C, et al. Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proc Natl Acad Sci U S A. 2008;105(11):4318–22.PubMedCentralPubMed
115.
Lezzi S, Di Padova M, Serra C, et al. Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. Dev Cell. 2004;6(5):673–84.
116.
Minetti GC, Colussi C, Adami R, et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med. 2006;12(10):1147–50.PubMed
117.
Wojcik S, Engel WK, McFerrin J, Askanas V. Myostatin is increased and complexes with amyloid-beta within sporadic inclusion-body myositis muscle fibers. Acta Neuropathol. 2005;110(2):173–7.PubMed
118.
McFarlane C, Plummer E, Thomas M, et al. Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. J Cell Physiol. 2006;209(2):501–14.PubMed
119.
Li YP, Chen Y, John J, et al. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J Off Publ Fed Am Soc Exp Biol. 2005;19(3):362–70.
120.
Lee HK, Rocnik E, Fu Q, et al. Foxo/atrogin induction in human and experimental myositis. Neurobiol Dis. 2012;46(2):463–75.PubMedCentralPubMed
121.
Mammen AL, Casciola-Rosen LA, Hall JC, Christopher-Stine L, Corse AM, Rosen A. Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum. 2009;60(12):3784–93.PubMedCentralPubMed
122.
Greenberg SA. Pathogenesis and therapy of inclusion body myositis. Curr Opin Neurol. 2012;25(5):630–9.PubMed
123.
Machado P, Miller A, Herbelin L, et al. Safety and tolerability of arimoclomol in patients with sporadic inclusion body myositis: a randomised, double-blind, placebo-controlled, phase IIa proof-of-concept trial. Ann Rheum Dis. 2013;72 Suppl 3:164.
124.
125.
126.
Amato AA, Sivakumar K, Goyal N, et al. Treatment of sporadic inclusion body myositis with an anti-activin receptor IIB antibody. Ann Neurol. 2013;74:S93–4.
127.
128.
Kohl HW, Craig CL, Lambert EV, et al. The pandemic of physical inactivity: global action for public health. Lancet. 2012;380(9838):294–305.PubMed
129.•
Alemo Munters L, Alexanderson H, Crofford LJ, Lundberg IE. New insights into the benefits of exercise for muscle health in patients with idiopathic inflammatory myositis. Curr Rheumatol Rep. 2014;16(7):429. Recent review article about the beneficial effects of exercise in polymyositis, dermatomyositis, and IBM. PubMed
130.
Fowler WM, Jr. Consensus conference summary: role of physical activity and exercise training in neuromuscular diseases. J Phys Med. 2002;81(11).
131.
Spector SA, Lemmer JT, Koffman BM, et al. Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Muscle Nerve. 1997;20(10):1242–8.PubMed
132.
Arnardottir S, Alexanderson H, Lundberg IE, Borg K. Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehabil Med. 2003;35(1):31–5.PubMed
133.
Johnson LG, Edwards DJ, Walters S, Thickbroom GW, Mastaglia FL. The effectiveness of an individualized, home-based functional exercise program for patients with sporadic inclusion body myositis. J Clin Neuromuscul Dis. 2007;8(4).
134.
Lowes LP, Alfano L, Viollet L, et al. Knee extensor strength exhibits potential to predict function in sporadic inclusion-body myositis. Muscle Nerve. 2012;45(2):163–8.PubMed
135.
Gualano B, Ugrinowitsch C, Neves Jr M, et al. Vascular occlusion training for inclusion body myositis: a novel therapeutic approach. J Vis Exp. 2010(40).
136.
McCrory MA, Kim HR, Wright NC, Lovelady CA, Aitkens S, Kilmer DD. Energy expenditure, physical activity, and body composition of ambulatory adults with hereditary neuromuscular disease. Am J Clin Nutr. 1998;67(6):1162–9.PubMed
137.
Taivassalo T, De Stefano N, Chen J, Karpati G, Arnold D, Argov Z. Short-term aerobic training response in chronic myopathies. Muscle Nerve. 1999;22(9):1239–43.PubMed
138.
Wiesinger GF, Quittan M, Nuhr M, et al. Aerobic capacity in adult dermatomyositis/polymyositis patients and healthy controls. Arch Phys Med Rehabil. 2000;81(1):1–5.PubMed
139.
Johnson LG, Collier KE, Edwards DJ, et al. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. J Clin Neuromuscul Dis. 2009;10(4):178–84.PubMed
140.
American Thoracic Society - ATS, American College of Chest Physicians - ACCP. ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003;167(2):211–77.
141.
Jones K, Whittaker R, Miller J, Jakovljevic D, Turnbull D, Gorman G. The effects of high intensity interval training on clinical symptoms and functional capacity in adults with neuromuscular disease. J Neurol Neurosurg Psychiatry. 2013;84(11):e2.
142.
Phillips M, Flemming N, Tsintzas K. An exploratory study of physical activity and perceived barriers to exercise in ambulant people with neuromuscular disease compared with unaffected controls. Clin Rehabil. 2009;23(8):746–55.PubMed
143.
Wallace A, Dewar L, Skorupinska M, et al. Evaluating the benefits of community based aerobic training on the physical health and well-being of people with neuromuscular diseases: a pilot study. J Peripher Nerv Syst. 2013;18(S2).
Metadata
Title
Ongoing Developments in Sporadic Inclusion Body Myositis
Authors
Pedro M. Machado
Mhoriam Ahmed
Stefen Brady
Qiang Gang
Estelle Healy
Jasper M. Morrow
Amanda C. Wallace
Liz Dewar
Gita Ramdharry
Matthew Parton
Janice L. Holton
Henry Houlden
Linda Greensmith
Michael G. Hanna
Publication date
01-12-2014
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 12/2014
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-014-0477-9

Other articles of this Issue 12/2014

Current Rheumatology Reports 12/2014 Go to the issue

Pediatric Rheumatology (S Ozen, Section Editor)

The Presentation, Assessment, Pathogenesis, and Treatment of Calcinosis in Juvenile Dermatomyositis

Health Economics and Quality of Life (M Harrison, Section Editor)

Economics of Stratified Medicine in Rheumatoid Arthritis

Inflammatory Muscle Disease (RG Cooper, Section Editor)

Myositis Specific and Associated Autoantibodies in the Diagnosis and Management of Juvenile and Adult Idiopathic Inflammatory Myopathies

Inflammatory Muscle Disease (RG Cooper, Section Editor)

Amyopathic Dermatomyositis: Definitions, Diagnosis, and Management

Pediatric Rheumatology (S Ozen, Section Editor)

Enthesitis-Related Arthritis: Time to Re-define?

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits